FDA & Government News
Feature

MHRA Approval for First UK-made mRNA Vaccine

Moderna receives MHRA approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

  • By

  • February 27, 2026

  • 2 min

Share

Moderna's updated COVID-19 mRNA vaccine, Spikevax®, has received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for individuals aged six months and older, targeting the SARS-CoV-2 LP.8.1 variant. The vaccine will be supplied for the NHS COVID-19 vaccination campaign in spring 2026. Darius Hughes, UK General Manager of Moderna, emphasized its importance in public health and the collaboration between government and industry to bolster vaccine manufacturing within the UK, enhancing future pandemic resilience.

Original Source(s)

MHRA Approval for First UK-made mRNA Vaccine

Moderna receives MHRA approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

  • February 27, 2026

  • 2 min

Related Content

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

When Obesity Meets Infection Risk

Researchers analyze data from Finnish cohorts and the UK Biobank to examine how body mass index relates to severe infections and their global burden.